化疗联合唑来膦酸对肺癌骨转移的疗效及炎性因子的影响

Influence of Chemotherapy Combined with Zoledronic Acid on the Efficacy and Inflammatory Factors of Lung Cancer Bone Metastases

目的:探讨化疗联合唑来膦酸对肺癌患者骨转移的疗效及炎性因子的影响。方法:回顾性选择我院2010年1月至2015年12月收治的84例肺癌骨转移患者,根据随机数字表法结合患者意愿,将所有患者平均分为观察组与对照组,每组42例。对照组给予TP方案化疗2个疗程,观察组在对照组基础上给予唑来膦酸治疗2个疗程,观察两组患者治疗后的镇痛效果、活动能力、骨转移灶效果、不良反应及治疗前后的IL-6、TNF-α水平。结果:观察组镇痛效果、活动能力、骨转移灶效果明显高于对照组(P<0.05),观察组与对照组不良反应无统计学意义(P>0.05),与治疗前相比,治疗后两组患者的IL-6、TNF-α水平明显降低,与对照组相比,治疗后治疗组的IL-6、TNF-α水平明显较低(P<0.05)。结论:化疗联合唑来膦酸治疗肺癌骨转移安全有效,可降低炎性因子的释放,增强镇痛效果和活动能力,减缓骨转移。

Objective： To investigate the clinical efficacy of chemotherapy combined with zoledronic acid in lung cancer with bone metastases and its effect on inflammatory factors. Methods： 84 lung cancer patients with bone metastasis from January 2010 to December 2015 in our hospital were chosen and divided into observation group and control group, 42 cases in each group. The control group was given TP chemotherapy regimen for 2 courses, and the observation group were given zoledronic acid combined with chemotherapy for 2 courses. The analgesic effect, activity ability, bone metastases effect, adverse reactions were detected, and the level of IL-6 and TNF-αbefore and after treatment were observed and compared. Results： The analgesic effect, activity ability, bone metastases effect in the observation group were higher than that of control group（P〈0.05）, the incidence of adverse reactions of two groups had no significant difference（P〉0.05）, the IL-6 and TNF-α level in two groups after treatment was obviously lower than before treatment, and the IL-6 and TNF-α in the observation group were lower than that of control group（P〈0.05）. Conclusions： Chemotherapy combined with zoledronic acid can reduce the inflammation factors release, enhance the analgesic effect and activity ability, and alleviate bone metastases.